Directorate Update and Grant of Options

RNS Number : 0636Q

Redx Pharma plc

04 June 2018

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN

REDX PHARMA PLC

("Redx" or "the Company")

Directorate Update

& Grant of Options

Lisa Anson assumes role as Chief Executive Officer 

Alderley Park, 4 June 2018 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that, further to the announcement made on 24 April 2018, Lisa Anson assumed her new role as Chief Executive Officer on 1 June 2018 and has become a member of Redx Pharma's Board of Directors.  Iain Ross has reverted to the role of Non-Executive Chairman.

In addition the company announces that on 1 June 2018 options over 3,600,000 ordinary shares of 1p each in the share capital of the Company, were granted to Lisa Anson, Chief Executive Officer, on the following basis:

Granted 1,800,000 Options under Redx's Enterprise Management Incentive Scheme. 

600,000 options are exercisable at a price of 13.75p and will vest immediately

600,000 options are exercisable at a price of 20p and will vest immediately

600,000 options are exercisable at a price of 27p and will vest on the 1-year anniversary of the grant,

Granted 1,800,000 Unapproved Options

600,000 options are exercisable at a price of 35p and will vest on the 1-year anniversary of the grant,

600,000 options are exercisable at a price of 42.5p p and will vest on the 2-year anniversary of the grant.

600,000 options are exercisable at a price of 50p and will vest on the 2-year anniversary of the grant.

None of these options will become exercisable until the second anniversary of grant.

-Ends-

For further information, please contact:

Redx Pharma Plc	T: [phone]
Iain Ross, Chairman
Cantor Fitzgerald Europe (Nominated Advisor & Broker)	T: [phone]
Phil Davies
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting	T: [phone]
Simon Conway/Stephanie Cuthbert

About Redx Pharma Plc 

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Lisa Anson
2	Reason for notification
a.	Position/Status	Chief Executive Officer
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Redx Pharma Plc
b.	LEI	213800HMS4EBXO589Y37
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over Ordinary Shares of 1p each ISIN: GB00BSNB6S51
b.	Nature of the transaction	Grant of options under the EMI Share Scheme Grant of Unapproved Options
c.	Price(s) and volume(s)	Granted 1,800,000 Options under Redx's Enterprise Management Incentive Scheme. 600,000 options are exercisable at a price of 13.75p and will vest immediately 600,000 options are exercisable at a price of 20p and will vest immediately 600,000 options are exercisable at a price of 27p and will vest on the 1-year anniversary of the grant, Granted 1,800,000 Unapproved Options 600,000 options are exercisable at a price of 35p and will vest on the 1-year anniversary of the grant, 600,000 options are exercisable at a price of 42.5p p and will vest on the 2-year anniversary of the grant. 600,000 options are exercisable at a price of 50p and will vest on the 2-year anniversary of the grant.
d.	Aggregated information - Aggregated Volume - Price	N/A - Single Transaction
e.	Date of the transaction	01/06/18
f.	Place of the transaction	Outside of trading venue

 

END

 

 

DSHLLFEFRRILIIT